
In some regions, varying levels of logistics infrastructure, like cold chain storage equipment, and unreliable access to electricity and the internet can make last-mile distribution more challenging. Less than 5 percent of people in low-income countries have received at least one dose, according to reports.

While the global vaccination rate continues to climb, distribution efforts in some countries in Asia and Africa still lag far behind due, in part, to limited supply. Because of their commitment and exemplary work, we’ve been able to provide communities across Europe reliable access to COVID-19 vaccines, as well as the treatment they need every day.” “We’re incredibly proud of our front-line workers. “Since the start of the pandemic, our teams have worked tirelessly to safeguard the pharmaceutical supply chain and ensure access to critical pharmaceutical products, including COVID-19 vaccines,” said Juan Guerra, SVP & Managing Director of Alliance Healthcare. In the UK, for example, Alliance Healthcare and Alloga, its healthcare logistics business, worked with the National Health Service to build robust strategies, enabling them to deliver about 35 million vaccine doses to nearly 1,500 sites of care thus far. Thousands of miles away, teams at Alliance Healthcare-a leading pharmaceutical wholesaler in Europe that AmerisourceBergen acquired in June-have distributed more than 50 million COVID-19 vaccines across the UK, France, Spain, Czech Republic and Lithuania.


Through its network of global businesses and capabilities, AmerisourceBergen has supported the distribution of more than 100 million COVID-19 vaccine doses across 30-plus countries, providing an array of logistical services and support like third-party logistics (3PL), importation and temperature-controlled packaging and storage.Īs part of an agreement with the Government of Canada, Innomar Strategies, a part of AmerisourceBergen, has worked FedEx Express Canada to distribute more than 30 million COVID-19 vaccine doses across Canada’s vast geography, including deliveries to remote communities in the Northwest Territories. “While much work is still needed, the tremendous innovation and collaboration across the industry to develop and then distribute billions of COVID-19 vaccine doses worldwide within such a short timeframe underscores the value and efficiency of this industry,” said Doug Cook, EVP and President, Business Group-Global, at AmerisourceBergen. However, the lessons learned from this distribution effort-and the challenges introduced over the last 18 months-will result in lasting changes and new considerations that strengthen the global pharmaceutical supply chain and help drive increased product access worldwide. With just over half of the world’s population having received at least one dose, the roll out of COVID-19 vaccine doses is still far from over. Now more than ever, there is a heightened focus on the development and ensuing distribution of pharmaceutical products-including the solutions, expertise and collaboration needed to deliver temperature-sensitive vaccines from a manufacturer’s facility to all corners of the world, on-time and in the right condition.

The unprecedented scale of the COVID-19 pandemic and the distribution of billions of vaccine doses and therapies worldwide has put an increasingly large spotlight on the global pharmaceutical supply chain.
